Gene therapy isn’t supposed to scale. That’s the whispered assumption buried in conference halls and investment decks, the belief that curing chronic disease with engineered viruses is too expensive, too complicated, too bespoke. Then Kriya Therapeutics shows up, pulls in a $320 million oversubscribed Series D, and makes the skeptics look like they bet on dial-up in a 5G world. Patient Square Capital and Premji Invest led the round, Peter Thiel, Narya Capital, and The T1D Fund joined in, and Akshay Rai of Premji Invest grabbed a board seat. That’s not just capital, it’s conviction.
This story runs through the founders. Shankar Ramaswamy, M.D., Harvard economist turned Brown-trained physician, saw the cracks at Roivant and Axovant before deciding the system needed a rebuild. Fraser Wright, Ph.D., designed the engine that powered Spark Therapeutics to the first FDA-approved gene therapy. Roger Jeffs, Ph.D., proved at United Therapeutics that rare diseases could be turned into regulated wins. Put them together and you get a doctor, a manufacturing savant, and a commercial closer, exactly the kind of founding chemistry you want if your goal is to bend the cost curve of an entire field.
The pipeline reads like a punch list of chronic conditions medicine has struggled to move past: Geographic Atrophy, Thyroid Eye Disease, Type 1 Diabetes, Metabolic-Associated Steatohepatitis, Trigeminal Neuralgia. Each hits millions. Each drains healthcare systems. Each sits in markets worth billions. Kriya isn’t chasing academic trophies, it’s chasing scale, using an integrated CMC “factory-in-a-box” to bring down the cost and complexity that’s kept gene therapy from breaking out of rare disease silos.
The depth of the team makes that vision credible. Curt Herberts running operations. Michele Stone, Ph.D., advancing the science. Brian Furmanski, Ph.D., steering development. Britt Petty building manufacturing muscle. Katherine Eade, J.D., locking in legal. A bench of senior VPs spanning nonclinical, analytics, clinical, IP, and people operations. Nearly 200 employees across RTP and Palo Alto moving in rhythm, backed by GMP facilities aligned with FDA and EMA standards. That’s not a biotech garage band, it’s a symphony.
Since its $15 million seed in 2019, Kriya has raised more than $900 million, including an $80.5 million Series A and a $270 million Series C. Those numbers aren’t vanity, they’re signals that execution beats hype. Investors aren’t buying into theoretical capsid slides; they’re betting on a platform that’s already built, staffed, and scaling. By 2026, early readouts in ophthalmology and metabolic disease will test whether Kriya’s thesis holds. Until then, $320 million says gene therapy might finally be ready to trade boutique status for mainstream medicine.
